Clinical Trial Update: Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for VT-464 in patients with castration-resistant prostate cancer previously treated with enzalutamide, androgen receptor–positive …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Androgen Receptor-positive Triple-negative Breast Cancer
• Castration-resistant Prostate Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• VT-464

Snippet

Sponsor: Innocrin Pharmaceutical | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED